MYC protein interactors in gene transcription and cancer
The transcription factor and oncoprotein MYC is a potent driver of many human cancers and
can regulate numerous biological activities that contribute to tumorigenesis. How a single …
can regulate numerous biological activities that contribute to tumorigenesis. How a single …
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …
Accurate and efficient detection of gene fusions from RNA sequencing data
S Uhrig, J Ellermann, T Walther, P Burkhardt… - Genome …, 2021 - genome.cshlp.org
The identification of gene fusions from RNA sequencing data is a routine task in cancer
research and precision oncology. However, despite the availability of many computational …
research and precision oncology. However, despite the availability of many computational …
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
Summary The KRAS G12D mutation is present in nearly half of pancreatic adenocarcinomas
(PDAC). We investigated the effects of inhibiting the KRAS G12D mutant protein with …
(PDAC). We investigated the effects of inhibiting the KRAS G12D mutant protein with …
Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC);
however, resistance is common. Among patients with KRAS G12C-mutant PDAC treated …
however, resistance is common. Among patients with KRAS G12C-mutant PDAC treated …
Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy
T Cascone, JA McKenzie, RM Mbofung, S Punt… - Cell metabolism, 2018 - cell.com
Adoptive T cell therapy (ACT) produces durable responses in some cancer patients;
however, most tumors are refractory to ACT and the molecular mechanisms underlying …
however, most tumors are refractory to ACT and the molecular mechanisms underlying …
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Interactions between WD40 repeat domain protein 5 (WDR5) and its various partners such
as mixed lineage leukemia (MLL) and c-MYC are essential for sustaining oncogenesis in …
as mixed lineage leukemia (MLL) and c-MYC are essential for sustaining oncogenesis in …
The role of histone methylation in the development of digestive cancers: a potential direction for cancer management
Y Chen, B Ren, J Yang, H Wang, G Yang… - Signal transduction and …, 2020 - nature.com
Digestive cancers are the leading cause of cancer-related death worldwide and have high
risks of morbidity and mortality. Histone methylation, which is mediated mainly by lysine …
risks of morbidity and mortality. Histone methylation, which is mediated mainly by lysine …
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains recalcitrant to all forms of cancer
treatment and carries a five-year survival rate of only 8%. Inhibition of oncogenic KRAS …
treatment and carries a five-year survival rate of only 8%. Inhibition of oncogenic KRAS …
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic
Abstract WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine
methyltransferase complex, is critically involved in oncogenesis and represents an attractive …
methyltransferase complex, is critically involved in oncogenesis and represents an attractive …